Digestery
Longevity supplements › Metformin and Aging › Studies

Randomized trial · measured lab tests or safety

A trial in 20 healthy older adults: metformin lessened muscle shrinkage during bed rest

Petrocelli and colleagues · Aging cell · 2023

Original title: Disuse-induced muscle fibrosis, cellular senescence, and senescence-associated secretory phenotype in older adults are alleviated during re-ambulation with metformin pre-treatment.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Metformin-treated people had less type-I muscle fiber shrinkage during bed rest, less inflammation signals and less muscle collagen during recovery. Cell aging (senescence) markers were lower too.

The study at a glance

Type of study
Randomized trial
Who or what was studied
20 people · Healthy older adults aged 60 and over, not obese
What was tested
Metformin vs placebo for 2 weeks before, then during 5 days of bed rest, stopped for 7 days of recovery
What it measured
Lab tests or markers
How long
4 weeks
Trial registration
NCT03107884
Who has a stake
No stake declared
No competing interests declared.
Journal
Aging cell, 2023
Source
PubMed record 37486024. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 20 people. Small trials can miss real effects or find chance ones.
  • –Short: 4 weeks. Longer-term effects are unknown.
  • –Measured lab tests or markers, which stand in for aging, frailty and death in people without diabetes. A better marker does not always mean better health.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

    ↑ This study is the ringed dot

  4. Population studies

    8

    6 benefit, 2 no difference

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 5 papers on the same step: 1 benefit, 2 mixed, 2 no difference. This one found benefit.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.